Loading
A phase 2 trial of Darbepoetin alfa, Pegfilgrastim, Cisplatin and Docetaxel in Lung cancer, run by Alliance for Clinical Trials in Oncology, completed.
Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT00077311 by Alliance for Clinical Trials in Oncology, with 160 participants recorded, started 2004-08 and reaching its primary completion in 2006-07. Interventions recorded: darbepoetin alfa, pegfilgrastim, cisplatin, docetaxel, BNP7787. Conditions recorded: Anemia, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Neutropenia.
Linked to the drug Darbepoetin alfa because the registry names it among its interventions and Lung cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Darbepoetin alfa, Pegfilgrastim and the tag pipeline.
Shares Darbepoetin alfa and the tag pipeline.
Shares Pegfilgrastim, Docetaxel and the tag pipeline.
Shares Pegfilgrastim, Docetaxel and the tag pipeline.
Shares Pegfilgrastim, Docetaxel and the tag pipeline.
Shares Alliance for Clinical Trials in Oncology and the tag pipeline.